The vaccine hope from Curevac from Tübingen in Baden-Württemberg is still not approved. Disappointing study results on the vaccine have now become known.
Tübingen – The biotech company Curevac from Tübingen has been working on a vaccine against the coronavirus since February 2020. In the meantime, vaccines from several manufacturers are being used in the southwest, but approval for the mRNA active ingredient from Curevac is being delayed further and further. The vaccine has been in the final and approval-relevant study phase for around a year. Yesterday, Wednesday, the company published a mandatory stock market report on the effectiveness of the vaccine. The effect is significantly less than that of the competition. As BW24 * reports, Curevac shares are falling dramatically – vaccine is only 47 percent effective.
Curevac's mRNA vaccine has long been considered a hope for the vaccination campaign (BW24 * reported). * BW24 is an offer from IPPEN.MEDIA.
